Cargando…
Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma
Autologous peripheral blood haematopoietic stem cell transplantation (HCT) cures 33%–40% of dogs with high‐grade B‐cell lymphoma. We hypothesized, based on human allogeneic bone marrow transplantation literature, that transplanting dogs using canine donor leukocyte‐matched CD34+ cells would lead to...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796125/ https://www.ncbi.nlm.nih.gov/pubmed/35789057 http://dx.doi.org/10.1111/vco.12847 |
_version_ | 1784860412369436672 |
---|---|
author | Gareau, Alexandra Sekiguchi, Tomoko Warry, Emma Ripoll, Alexandra Z. Sullivan, Edmund Westfall, Theresa Chretin, John Fulton, Lisa M. Harkey, Michael Storb, Rainer Suter, Steven E. |
author_facet | Gareau, Alexandra Sekiguchi, Tomoko Warry, Emma Ripoll, Alexandra Z. Sullivan, Edmund Westfall, Theresa Chretin, John Fulton, Lisa M. Harkey, Michael Storb, Rainer Suter, Steven E. |
author_sort | Gareau, Alexandra |
collection | PubMed |
description | Autologous peripheral blood haematopoietic stem cell transplantation (HCT) cures 33%–40% of dogs with high‐grade B‐cell lymphoma. We hypothesized, based on human allogeneic bone marrow transplantation literature, that transplanting dogs using canine donor leukocyte‐matched CD34+ cells would lead to fewer relapses and increased cure rates. We retrospectively reviewed medical records of dogs diagnosed with high‐grade B‐cell lymphoma who received an identical allogeneic HCT. A total of 15 dogs transplanted at four facilities were identified. Five of fifteen dogs relapsed before transplant. The mean number of donor CD34+ cells/kg harvested and infused into recipient dogs was 8.0 × 10(6)/kg (range: 2.08 × 10(6)/kg–2.9 × 10(7)/kg). The median disease‐free interval and overall survival of all dogs was 1095 days (range: 9–2920 days) and 1115 days (range: 9–2920 days), respectively. Two of five dogs, not in remission at transplant, died in the hospital. The median disease‐free interval and overall survival of the remaining three dogs was 25 days (range: 15–250 days) and 1100 days (range: 66–1902 days), respectively. The median disease‐free interval and overall survival of the 10 dogs who had not relapsed was 1235 days (range: 19–2920 days) and 1235 days (range: 19–2920 days), respectively. One dog died soon after discharge of presumed gastric‐dilatation‐volvulus. Eight of nine remaining dogs lived >4 yrs post‐alloHCT, leading to a cure rate of 89%. Acute graft versus host disease was seen in three dogs. These results suggest that allogeneic HCT can cure ~50% more dogs than those treated with autologous HCT. |
format | Online Article Text |
id | pubmed-9796125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-97961252022-12-30 Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma Gareau, Alexandra Sekiguchi, Tomoko Warry, Emma Ripoll, Alexandra Z. Sullivan, Edmund Westfall, Theresa Chretin, John Fulton, Lisa M. Harkey, Michael Storb, Rainer Suter, Steven E. Vet Comp Oncol Original Articles Autologous peripheral blood haematopoietic stem cell transplantation (HCT) cures 33%–40% of dogs with high‐grade B‐cell lymphoma. We hypothesized, based on human allogeneic bone marrow transplantation literature, that transplanting dogs using canine donor leukocyte‐matched CD34+ cells would lead to fewer relapses and increased cure rates. We retrospectively reviewed medical records of dogs diagnosed with high‐grade B‐cell lymphoma who received an identical allogeneic HCT. A total of 15 dogs transplanted at four facilities were identified. Five of fifteen dogs relapsed before transplant. The mean number of donor CD34+ cells/kg harvested and infused into recipient dogs was 8.0 × 10(6)/kg (range: 2.08 × 10(6)/kg–2.9 × 10(7)/kg). The median disease‐free interval and overall survival of all dogs was 1095 days (range: 9–2920 days) and 1115 days (range: 9–2920 days), respectively. Two of five dogs, not in remission at transplant, died in the hospital. The median disease‐free interval and overall survival of the remaining three dogs was 25 days (range: 15–250 days) and 1100 days (range: 66–1902 days), respectively. The median disease‐free interval and overall survival of the 10 dogs who had not relapsed was 1235 days (range: 19–2920 days) and 1235 days (range: 19–2920 days), respectively. One dog died soon after discharge of presumed gastric‐dilatation‐volvulus. Eight of nine remaining dogs lived >4 yrs post‐alloHCT, leading to a cure rate of 89%. Acute graft versus host disease was seen in three dogs. These results suggest that allogeneic HCT can cure ~50% more dogs than those treated with autologous HCT. Blackwell Publishing Ltd 2022-07-26 2022-12 /pmc/articles/PMC9796125/ /pubmed/35789057 http://dx.doi.org/10.1111/vco.12847 Text en © 2022 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Gareau, Alexandra Sekiguchi, Tomoko Warry, Emma Ripoll, Alexandra Z. Sullivan, Edmund Westfall, Theresa Chretin, John Fulton, Lisa M. Harkey, Michael Storb, Rainer Suter, Steven E. Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma |
title | Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma |
title_full | Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma |
title_fullStr | Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma |
title_full_unstemmed | Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma |
title_short | Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade B‐cell lymphoma |
title_sort | allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high‐grade b‐cell lymphoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796125/ https://www.ncbi.nlm.nih.gov/pubmed/35789057 http://dx.doi.org/10.1111/vco.12847 |
work_keys_str_mv | AT gareaualexandra allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT sekiguchitomoko allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT warryemma allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT ripollalexandraz allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT sullivanedmund allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT westfalltheresa allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT chretinjohn allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT fultonlisam allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT harkeymichael allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT storbrainer allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma AT suterstevene allogeneicperipheralbloodhaematopoieticstemcelltransplantationforthetreatmentofdogswithhighgradebcelllymphoma |